Entropy Neurodynamics (ASX:ENP)
ASX announcement history & article coverage
Transparent by design.
Announcments by Entropy Neurodynamics (ASX:ENP) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Investor Webinar Presentation
Appendix 4G and Corporate Governance Statement
Appendix 4E and 2026 Annual Report
Entropy Neurodynamics reports improved FY26 results and promising clinical progress with TRP-8803 in Binge Eating Disorder
Entropy Advances TRP-8803 to US Phase 2 in Depression
Application for quotation of securities - ENP
Trading Halt
TRP 8803 manufacturing secured for Phase 2/3 advancement
Entropy Neurodynamics partners with BioCina for GMP manufacturing of TRP-8803 psilocin formulation
Change of Director's Interest Notice - HJ
Cleansing Notice
Application for quotation of securities - ENP
BioShares 2026 Investor Presentation Deck
72-Patient Trial Fast-Tracks TRP-8803 Commercialisation
Trading Halt
Techknow Invest Roadshow presentation
Appointment of Joint Company Secretary
Quarterly Activities Report and Appendix 4C
Entropy Neurodynamics reports strong Phase 2 clinical results in BED and IBS, advances TRP-8803 development and IP portfolio
South Africa Grants ENP Broad Fibromyalgia Patent to 2043
Entropy Neurodynamics granted South African patent for psilocybin fibromyalgia treatment
Additional Australian patent granted
Investor Presentation
100% Clinical improvement, 50% Remission in BED study
Trading Halt
Application for quotation of securities - ENP
Top 20 Option Holders & Distribution Schedule
Proposed issue of securities - ENP
Short Form Prospectus
DSMB Clears TRP 8803 to Advance to Cohort 2
Entropy Neurodynamics DSMB endorses safe progression of TRP-8803 Binge Eating Disorder trial to Cohort 2
Entropy completes Cohort 1 dosing in BED trial
Entropy Neurodynamics completes first cohort dosing in Phase 2 BED trial of TRP-8803
